Skip to main content
logo
HomeStocksAUROPHARMA

A

Aurobindo Pharma

₹ 1,807.20

-20.30 (-1.11%)loss
as on 12 Nov 2026 at 03:55 PM
views130
portfolio1.2K
analyst66.67% Buy
Overview
Pros & Cons
News
History
Fundamentals
Investment Returns
Technicals
Financials
Balance Sheet
Cash Flow
Corporate Actions
FnO
Peers

Aurobindo Pharma Share Price Today

Aurobindo Pharma (AUROPHARMA) share price is trading at ₹1,807.20 on the NSE as of November 12, 2026 at 03:55 PM, down by 1.11% from its previous close of ₹1,827.50. In todays trading session AUROPHARMA reached a high of 1,821.10 and low of 1,785.40. The average traded price for today is 1,803.36. The 50 DMA stands at 1,687.81 and 200 DMA is at 1,484.50. Looking at intraday trend, the stock is in Downtrend.

Stock Overview

  • Symbol : AUROPHARMA
  • Open : ₹1,813.10
  • Previous Close : ₹1,827.50
  • Day's Range : ₹1,785.40 – ₹1,821.10
  • 52-Week Range : ₹1,106.00 – ₹1,859.90
Trading Charts Logo

Get 20+ Chart Types, 180+ Indicators, 80+ Drawing Tools & Create Custom Indicators for FREE.

Go to Charts

AUROPHARMA Stock Performance

Markets Today

High

1,821.10

Low

1,785.40

Open at

1,813.10

Prev Close

1,827.50

Volumes

22,74,622

Avg Price

1,803.36

Lower Circuit

1,626.50

Upper Circuit

1,987.90

Last Traded Details

Quantity

6

Time

15:55:18

Price Movement

1,785.401,821.10
1.22%Loss
down side
up side
0.76%Profit

Historical Performance

3 M High

1,859.90

3 M Low

1,547.70

1 Yr High

1,859.90

1 Yr Low

1,106.00

3 Yr High

1,859.90

3 Yr Low

958.50

5 Yr High

1,859.90

5 Yr Low

397.20

1-Year Performance

1,106.001,859.90
63.40%Loss
down side
up side
2.83%Profit

AUROPHARMA Pros and Cons

byfuzz AI

Consolidated Revenue grew from ₹8,286 Cr in Q2 FY26 to ₹10,263 Cr in Q2 FY27 — robust top-line expansion

Net Profit rose from ₹848 Cr in Q2 FY26 to ₹1,126 Cr in Q2 FY27 — consistent bottom-line growth

API Revenue increased from ₹961 Cr in Q2 FY26 to ₹1,162 Cr in Q2 FY27 — strong recovery in active ingredients

Domestic Loans fell from ₹1,764 Cr in Q2 FY26 to ₹604 Cr in Q2 FY27 — successful debt reduction

US Formulations Revenue jumped from ₹3,638 Cr in Q2 FY26 to ₹4,555 Cr in Q2 FY27 — key market recovery

Average FX rate climbed from 87.29 in Q2 FY26 to 95.55 in Q2 FY27 — persistent INR depreciation impacts costs

Foreign Exchange Loans rose from ₹5,720 Cr in Q2 FY26 to ₹7,628 Cr in Q2 FY27 — rising external debt exposure

Non-Beta-lactam API Revenue fluctuated from ₹292 Cr in Q2 FY26 to ₹304 Cr in Q2 FY27 — volatile segment performance

fuzz Insights
Positive

Factory profits dipped, but bank interest kept earnings flat.

Positive

US sales share dropped as Europe and Asia grew.

Neutral

Rupee weakness inflated sales, hiding flat local demand.

Neutral

One drug type is carrying the API business.

Neutral

Domestic debt cut, but foreign loans ballooned.

Negative

Sales grew 24%, but overheads grew 26%.

AUROPHARMA Analyst Rating

Buy

Analysts have suggested that investors can Buy this Stock

- By Refinitiv from 27 analysts

Buy

66.67%

Hold

18.52%

Sell

14.81%

Get forecast for Price, ROA & ROE based on analyst ratings.

Get Forecast

AUROPHARMA Share Price History

AUROPHARMA Fundamentals

Company Valuation

Market Cap (₹ Cr.)

1,03,982

PE Ratio

26.30

PB Ratio

2.67

Dividend Yield

0.38%

ROE

9.25%

ROCE

13.58%

Book Value (₹)

684.77

Face Value (₹)

1.00

Analyse AUROPHARMA with 12+ custom fundamentals and financial ratios.

Analyse Now

Share Holding Pattern

Held BySep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters
51.82%51.82%51.82%51.88%51.88%
Domestic Institutional Investors (DII)
27.60%27.68%25.87%25.10%24.42%
Foreign Institutional Investors (FII)
14.21%13.94%15.24%16.38%17.41%
Public Investors
5.25%5.36%5.74%5.36%5.02%
Government
0.00%0.00%0.00%0.00%0.00%

Promoters

Domestic Institutional Investors (DII)

Foreign Institutional Investors (FII)

Public Investors

Government

Aurobindo Pharma Return Calculator

Current value of ₹1,00,000 invested 5 years ago, as on today

₹ 0

Gain

₹ 1,00,000 (163.23%)

Note: Past profits do not guarantee future returns.

AUROPHARMA Investment Returns

1 Week

1 Month

3 Months

6 Months

9 Months

Create Wealth in Longterm with Weekly and Monthly SIP in Stocks.

AUROPHARMA Technicals

Moving Averages

PeriodSimpleSignal
5-SMA1,818.80Bearish
10-SMA1,764.37Bullish
20-SMA1,694.68Bullish
50-SMA1,687.81Bullish
100-SMA1,637.92Bullish
200-SMA1,484.50Bullish

Technical Indicators

IndicatorValueAction
RSI(14)64.35Neutral
ATR(14)43.66Less Volatile
STOCH(9,6)90.91Overbought
STOCH RSI(14)84.99Overbought
MACD(12,26)18.84Bullish
ADX(14)28.54Strong Trend

Summary of Technical Indicators for AUROPHARMA

Margin on AUROPHARMA

Order TypeMargin to PayLeverageQuantityTrade ValueMargin AmountActions

*Calculated on NSE. Applicable on all exchanges. Margins are subject to change from time to time or may be withdrawn under volatile market conditions. Intraday Orders are square-off automatically at 03:19 pm on NSE / BSE or on hitting 80% of margin utilisation (whichever earlier).

AUROPHARMA Financials Summary

View By:
Revenue
EBITDA
Net Profit
EPS
Revenue

In Crores

Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
8,3598,7938,8699,37010,396

AUROPHARMA Financials

View by

Income Statement

In Cr

Yearly StatementMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
23,77625,14629,55932,34634,145
Expenses19,06921,13723,15925,14126,807
4,7074,0096,4007,2057,338
Operating Profit4,3873,7195,8436,5836,846
Operating Profit Margin %19%15%20%21%20%
Other Income320291557622492
Interest49141290457384
Depreciation1,1271,2451,5221,6491,778
3,3732,6134,3805,0665,112
Tax %22%26%28%31%31%
Net Profit2,6471,9283,1693,4843,503
EPS4533546060

Balance Sheet

In Cr

Yearly Balance SheetMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
33,92239,89045,07249,78558,502
Fixed Assets10,53211,02414,49314,79417,407
Current Assets18,12321,46023,77227,16332,709
Capital Work in Progress3,7475,3903,8694,9005,214
Investments9975433722521,051
Other Assets18,64522,93426,33829,83934,831
33,92239,89045,07249,78558,502
Current Liabilities8,15611,49412,19914,68218,039
Non Current Liabilities1,1921,5443,0222,4562,580
24,57426,85229,85132,64737,883
Reserve & Surplus24,51726,78129,78432,59537,833
Share Capital5959595858
Minority Interest-2128-6-8

Cash Flow

In Cr

Yearly Cash FlowMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Activities5,0172,3872,4353,9255,526
Investing Activities-3,211-3,971-4,242-1,866-2,630
Financing Activities-2,9691,814800120-1,269
Net Cash Flow-1,164230-1,0072,1781,628

Corporate Actions

DateCorporate ActionInformation
11th Nov 2026, Wednesday
DIVIDENDDividend
Interim Dividend of ₹7/share
4th Nov 2026, Wednesday
QUARTERLY RESULT ANNOUNCEMENTStock Result
Q2 FY 26-27 Results
info
5th Aug 2026, Wednesday
QUARTERLY RESULT ANNOUNCEMENTStock Result
Q1 FY 26-27 Results
info
21st May 2026, Thursday
QUARTERLY RESULT ANNOUNCEMENTStock Result
Q4 FY 26-27 Results
info
17th Apr 2026, Friday
BUYBACKBuyback
₹ 1475/share

The above dates are ex-dates.

Check AUROPHARMA latest Company Filings, Investor Presentation & Conference Call details.

Read Now

AUROPHARMA Revenue Growth

All values are in Crores

Revenue

Profit

Loss

Financial YearRevenueRevenue GrowthNet ProfitProfit Growth
FY 2025-2611,759
4.42% profit
2,415
38.24% profit
FY 2024-2511,261
-0% profit
1,747
-10.61% Loss
FY 2023-2411,262
26.52% profit
1,900
59.25% profit

AUROPHARMA Options Snapshot

Option Chain
Top 5 Traded ContractsExpiry DateLtpChangeChange %VolumeOpen InterestOI Change %

AUROPHARMA Futures Snapshot

Monthly ContractsDays for ExpiryLTPChangeChange %VolumeOpen InterestOI Change %
AUROPHARMA NOV FUT12

1,815.20

-9.60-0.5325,33,8501,47,03,1503.52
AUROPHARMA DEC FUT48

1,825.50

-9.10-0.501,22,1003,70,1509.79
AUROPHARMA JAN FUT75

1,821.70

-21.70-1.183,85026,400-2.04

Use from 12+ Pre-built Strategies or Build Your Own to trade AUROPHARMA FnO contracts.

Create Strategy

AUROPHARMA Similar Stocks

Name
LTP
Change %
Volume
Market Cap (Cr.)arrow
PE Ratio
Industry PE
52W High
52W Low
1M Returns
3M Returns
1 Yr Returns
3 Yr Returns
5 Yr Returns
PB Ratio
Dividend Yield
ROE
ROCE
EPS
50 DMA
200 DMA
RSI
Aurobindo Pharma

A

Aurobindo Pharma

1,807.20

-1.11%22,74,622₹ 1,03,98226.30-95.041,859.901,106.006.75%9.00%54.70%84.46%163.23%2.670.38%9.25%13.58%60.341,687.811,484.5064.35
Sun Pharmaceutical

S

Sun Pharmaceutical

1,885.00

-0.91%24,64,003₹ 4,52,27541.40-95.042,046.901,583.707.10%-2.94%9.84%59.83%137.15%5.100.84%13.79%17.94%47.801,821.871,815.3265.06
Divis Laboratories

D

Divis Laboratories

11,485.00

1.04%7,28,979₹ 3,04,89189.3018.7911,824.005,647.5022.97%33.88%75.63%228.78%137.62%16.690.26%15.32%18.96%96.759,579.407,507.0979.91
Torrent Pharmaceuticals

T

Torrent Pharmaceuticals

4,727.20

-0.71%2,84,834₹ 1,79,80786.3032.875,250.003,672.301.51%-3.25%23.56%129.68%233.54%9.860.80%12.16%9.06%63.924,763.974,543.4352.57
Laurus Labs

L

Laurus Labs

2,400.00

-1.19%17,65,796₹ 1,29,67598.70-95.042,488.00917.9517.84%29.17%143.48%550.49%419.26%21.710.04%16.38%19.67%16.472,073.221,507.9668.16
Zydus Life Science

Z

Zydus Life Science

1,206.00

0.54%19,78,474₹ 1,20,29927.60-95.041,266.60835.507.92%1.26%28.45%94.55%145.15%4.270.08%16.99%19.24%50.091,160.101,047.2556.86

FAQs on AUROPHARMA

Aurobindo Pharma share price as of today is ₹ 1,807.20 as on 12 Nov 2026 at 03:55 PM.
The 52W high of Aurobindo Pharma is ₹ 1,859.90 and 52W low is ₹ 1,106.00 as of 12 Nov 2026 at 15:55.
The past returns of Aurobindo Pharma share are -
  • Past 1 year: 54.70%
  • Past 3 years: 84.46%
  • Past 5 years: 163.23%
The PE and PB ratio of Aurobindo Pharma stands at 26.30 and 2.67 respectively as on 12 Nov 2026 at 15:55.
The EPS of Aurobindo Pharma is 19.57 for the quarter ended Sep 2026 and 60.34 for the financial year 2025-26.
The shareholding pattern of Aurobindo Pharma is as follows:
  • DIIs - 24.42%
  • FII - 17.41%
  • Promoters - 51.88%
  • Public Investors 5.02%
  • Goverenment - 0.00%
Yes, you can buy shares of Aurobindo Pharma online by opening Demat account with Dhan.
If you are a Dhan user already, you can buy Aurobindo Pharma stocks from Dhan Trading App or Web Trading Platform. If you are new to Dhan follow the below steps:
  1. Download the Dhan App to Open a Demat Account
  2. Navigate to the “Money Tab”
  3. Add money to your account
  4. Search for Aurobindo Pharma share
  5. Tap on “Buy”
With Dhan you can start a daily, weekly or monthly SIP in Aurobindo Pharma.
You can easily buy the shares of Aurobindo Pharma even after the markets are closed using the After Market Order feature on Dhan Trading App.


Explore  |  Sitemap

*All securities mentioned on this website are exemplary and not recommendatory.

*Current prices on the website are delayed by 15 mins, login to check live prices.

We are bullish on India, we are bullish on India's prospects to be one of the largest economies in the world. We believe that the stock market provides a unique opportunity for all of India's traders and investors to participate in the growth story of the country.

Yet, most investing & trading platforms in India have remained more or less the same over the past decade. Times have changed and retail traders and investors have become smarter about managing their trades and money. Modern traders & investors require an online trading platform that helps them keep up with the technological advancements of our time.

That's why we're building Dhan - to help you trade, to help you invest, and to help you participate in India's growth stock via the stock market with awesome features and an incredible experience.

©2021-2026 Raise Securities Private Limited (formerly Moneylicious Securities Private Limited). All rights reserved. CIN: U74999MH2012PTC433549 Raise Securities is part of Raise Financial Services and works closely with Raise Partners across services.

SEBI Stock Broker Registration No: INZ000006031 | Depository Participant (CDSL) ID: IN-DP-289-2016 | SEBI Research Analyst Registration No: INH000023357
Exchange Membership No. : NSE: 90133 | BSE: 6593 | MCX: 56320
Registered & Corporate Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai – 400104, Customer Care: 9987761000.


For any query / feedback / clarifications, email at help@dhan.co.

In case of grievances for any of the services rendered by Raise Securities Private Limited, please write to grievance@dhan.co (for NSE, BSE and MCX) or grievancedp@dhan.co (for Depository Participant). Please ensure that you carefully read the Risk Disclosure Document as prescribed by SEBI, our Terms of Use and Privacy Policy. Compliance Officer: Mr. Manish Garg and Mobile: 8655740961 Email: complianceofficer@dhan.co To lodge your complaints using SEBI SCORES, click here.


Disclaimer: All communications with the client via chat, phone, or email are for support purposes only. Any commitments or statements made by the agent (human or virtual) shall not be binding on the company.


DHAN is a brand owned by Raise Securities Private Limited. All DHAN clients are registered under Raise Securities Private Limited. Clients are advised to refer to our company as Raise Securities Private Limited when communicating with regulatory authorities.


Procedure to file a complaint on SEBI SCORES/SMART ODR Portal: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances. You may refer the website https://scores.sebi.gov.in/ for more information. You may also download the SEBI Scores app to log a complaint Android: https://play.google.com›store›apps›sebiscores iOS: https://apps.apple.com›app›sebiscores.


Disclaimer: Investment in the securities market are subject to market risks, read all the related documents carefully before investing. Brokerage will not exceed the SEBI prescribed limit


Attention investors:

  1. Stock brokers can accept securities as margins from clients only by way of pledge in the depository system w.e.f September 01, 2020.
  2. Update your e-mail and phone number with your stock broker / depository participant and receive OTP directly from depository on your e-mail and/or mobile number to create pledge.
  3. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month.

SEBI presents Samajh Se Investing Simple:

  • Understand Before You Invest
  • Choose Regulated Investment Products
  • Start Early, Stay Invested
  • Beware of Investment Frauds

Reporting of Short Sell Transactions by Clients:

Clients must report any short sale transaction, by emailing help@dhan.co with the subject “Reporting of Short Sell” on the same day.


Note: As a policy we do not give stock tips or recommendations and have not authorized anyone to give this on behalf of us. If you know anyone claiming to be a part of Dhan / / Raise or our associate companies or partners and offering such services, please report us on help@dhan.co. Important Information for Investors: To prevent unauthorized transactions in your trading / demat account, do not share your account details, credentials or any personal details with anyone. Keep your mobile number updated with your Stock Broker, Depository Participant and ensure that the same is registered with Stock Exchanges, Depository and KRAs. You will receive alerts and information on your registered mobile number / email for debit and other important transactions in your demat account directly from CDSL / Exchange on the same day. KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Stock Broker, DP, Mutual Fund, etc.), you need not undergo the same process again when you approach another intermediary. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account. This is issued in the interest of investors.


Investors should be cautious on unsolicited emails and SMS advising to buy, sell or hold securities and trade only on the basis of informed decision. Investors are advised to invest after conducting appropriate analysis of respective companies and not to blindly follow unfounded rumours, tips etc. Further, you are also requested to share your knowledge or evidence of systemic wrongdoing, potential frauds or unethical behaviour through the anonymous portal facility provided on BSE & NSE website. Issued in the interest of the investors.


Raise Securities Private Limited also known as Dhan is only an order collection platform that collects orders on behalf of clients and places them on BSE StarMF for execution. Client expressly agrees that Dhan is not liable or responsible and does not represent or warrant any damages regarding non- execution of orders or any incorrect execution of orders with regard to the funds chosen by the client or due to, but not being limited to, any link/system failure, delay in transfer of the funds on account of any unforeseen circumstances/issues in the banking system/payment aggregators or any other problems that may result in a delay in crediting the funds into the BSE Star MF's bank account. Raise Securities Private Limited (Dhan) does not engage in proprietary trading on its own account.


Mutual fund investments are subject to market risks, read all scheme related documents carefully before investing. Dhan is not a distributor or agent of any mutual fund. Mutual Funds are not exchange-traded products. Any related disputes will not have access to the Exchange-investor redressal forum or arbitration mechanism. For other disclaimers please refer https://dhan.co/advertisement-disclaimer/


Download client registration documents (Rights & Obligations, Risk Disclosure Document, Do's & Don'ts) in vernacular language: BSE | NSE | MCX


Kindly, read the Advisory Guidelines of BSE | NSE | MCX for investors as prescribed by the exchange with reference to their circular dated 27th August, 2021 regarding investor awareness and safeguarding client's assets


Important Links: SEBI | BSE | NSE | MCX | CDSL | SCORES | ODR Portal | Investor Charter for Stock Brokers | Investor Charter for DP | Investor Charter for Research Analyst | UCC Advisory | e-Voting for Shareholders | NCL Client Collateral details | MCXCCL Client Collateral details

Important Information: Terms of Usage | Disclaimers | Privacy Policy | Grievances | Grievances RA | Risk Management Policy | Risk Disclosure | Advertisement Disclaimer | Referral Terms & Conditions | Saarthi 2.0 Mobile App for Investors | Master Circular for Online Dispute Resolution